The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer

Kerstin Borgmann; Annette Raabe; Sebastian Reuther; Silke Szymczak; Thorsten Schlomm; Hendrik Isbarn; Maria Gomolka; Andreas Busjahn; Michael Bonin; Andreas Ziegler; Ekkehard Dikomey

doi:10.1016/j.radonc.2010.04.018

The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer

Kerstin Borgmann, Annette Raabe, Sebastian Reuther, Silke Szymczak, Thorsten Schlomm, Hendrik Isbarn, Maria Gomolka, Andreas Busjahn, Michael Bonin, Andreas Ziegler, Ekkehard Dikomey^*

^*Corresponding author for this work

Institute of Medical Biometry and Statistic

15 Citations (Scopus)

Abstract

Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors. Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay. Results: No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p = 1.75 ^-9). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%. Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.

Original language	English
Journal	Radiotherapy and Oncology
Volume	96
Issue number	1
Pages (from-to)	19-24
Number of pages	6
ISSN	0167-8140
DOIs	https://doi.org/10.1016/j.radonc.2010.04.018
Publication status	Published - 07.2010

Funding

The authors greatly acknowledge the technical assistance of Mrs. Alexandra Zielinski. This project was supported by Deutsches Bundesamt für Strahlenschutz with Grant No. StrSch4460 and in part (T.S.) also by Deutsches Bundesministerium für Bildung und Forschung in the framework of the program for medical genome research (FKZ:01GS08189).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.radonc.2010.04.018

Cite this

@article{10eaac38a8974359bb55415825dda9b9,

title = "The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer",

abstract = "Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors. Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay. Results: No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95\% CI: -0.18-0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95\% CI: -0.53 to -0.30, p = 1.75 -9). Using the 90\% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49\%. Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.",

author = "Kerstin Borgmann and Annette Raabe and Sebastian Reuther and Silke Szymczak and Thorsten Schlomm and Hendrik Isbarn and Maria Gomolka and Andreas Busjahn and Michael Bonin and Andreas Ziegler and Ekkehard Dikomey",

note = "Funding Information: The authors greatly acknowledge the technical assistance of Mrs. Alexandra Zielinski. This project was supported by Deutsches Bundesamt f{\"u}r Strahlenschutz with Grant No. StrSch4460 and in part (T.S.) also by Deutsches Bundesministerium f{\"u}r Bildung und Forschung in the framework of the program for medical genome research (FKZ:01GS08189).",

year = "2010",

month = jul,

doi = "10.1016/j.radonc.2010.04.018",

language = "English",

volume = "96",

pages = "19--24",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer

AU - Borgmann, Kerstin

AU - Raabe, Annette

AU - Reuther, Sebastian

AU - Szymczak, Silke

AU - Schlomm, Thorsten

AU - Isbarn, Hendrik

AU - Gomolka, Maria

AU - Busjahn, Andreas

AU - Bonin, Michael

AU - Ziegler, Andreas

AU - Dikomey, Ekkehard

N1 - Funding Information: The authors greatly acknowledge the technical assistance of Mrs. Alexandra Zielinski. This project was supported by Deutsches Bundesamt für Strahlenschutz with Grant No. StrSch4460 and in part (T.S.) also by Deutsches Bundesministerium für Bildung und Forschung in the framework of the program for medical genome research (FKZ:01GS08189).

PY - 2010/7

Y1 - 2010/7

N2 - Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors. Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay. Results: No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p = 1.75 -9). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%. Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.

AB - Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors. Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay. Results: No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p = 1.75 -9). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%. Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.

UR - https://www.scopus.com/pages/publications/77953958454

U2 - 10.1016/j.radonc.2010.04.018

DO - 10.1016/j.radonc.2010.04.018

M3 - Journal articles

C2 - 20452694

AN - SCOPUS:77953958454

SN - 0167-8140

VL - 96

SP - 19

EP - 24

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 1

ER -

The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this